Journal Home
Search for

Volume 72, Issue 1, Pages 236-246 (1 September 2008)


View previous. 37 of 62 View next.

Intrafractional Motion of the Prostate During Hypofractionated Radiotherapy

Yaoqin Xie, Ph.D., David Djajaputra, Ph.D., Christopher R. King, Ph.D., M.D., Sabbir Hossain, Ph.D., Lijun Ma, Ph.D., Lei Xing, Ph.D.Corresponding Author Informationemail address

Received 7 December 2007; received in revised form 10 April 2008; accepted 29 April 2008.

Purpose

To report the characteristics of prostate motion as tracked by the stereoscopic X-ray images of the implanted fiducials during hypofractionated radiotherapy with CyberKnife.

Methods and Materials

Twenty-one patients with prostate cancer who were treated with CyberKnife between January 2005 and September 2007 were selected for this retrospective study. The CyberKnife uses a stereoscopic X-ray system to obtain the position of the prostate target through the monitoring of implanted gold fiducial markers. If there is a significant deviation, the treatment is paused while the patient is repositioned by moving the couch. The deviations calculated from X-ray images acquired within the time interval between two consecutive couch motions constitute a data set.

Results

Included in the analysis were 427 data sets and 4,439 time stamps of X-ray images. The mean duration for each data set was 697 sec. At 30 sec, a motion >2 mm exists in about 5% of data sets. The percentage is increased to 8%, 11%, and 14% at 60 sec, 90 sec, and 120 sec, respectively. A similar trend exists for other values of prostate motion.

Conclusions

With proper monitoring and intervention during treatment, the prostate shifts observed among patients can be kept within the tracking range of the CyberKnife. On average, a sampling rate of ∼40 sec between consecutive X-rays is acceptable to ensure submillimeter tracking. However, there is significant movement variation among patients, and a higher sampling rate may be necessary in some patients.

 Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA

 Department of Radiation Oncology, University of California San Francisco, San Francisco, CA

Corresponding Author InformationReprint requests to: Lei Xing, Ph.D., Stanford University School of Medicine Department of Radiation Oncology, 875 Blake Wilbur Drive, Stanford, CA 94305-5847. Tel: (650) 498-7896; Fax: (650) 498-4015

 Conflict of interest: none.

PII: S0360-3016(08)00808-0

doi:10.1016/j.ijrobp.2008.04.051


View previous. 37 of 62 View next.